Brief: Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus NV

02/12/2024 13:24

Dec 2 (Reuters) - Merus NV  2GH.F :
    * MERUS AND PARTNER THERAPEUTICS ANNOUNCE LICENSE AGREEMENT
FOR
THE U.S. COMMERCIALIZATION OF ZENOCUTUZUMAB IN NRG1
FUSION-POSITIVE CANCER
    * MERUS NV - PTX TO ASSUME FULL U.S. COMMERCIALIZATION
RIGHTS OF
ZENO
    * MERUS NV - TO RECEIVE UPFRONT PAYMENT, MILESTONES, AND
ROYALTIES
FROM PTX

Source text:  ID:nGNX88sc3q 
Further company coverage:  2GH.F 

 ((Reuters.Briefs@thomsonreuters.com;))